H. Heslop

Publications779
h-index98
Citations37,043
Highly Influential Citations860
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • M. Brenner
  • 839 Publications • 44,726 Citations
  • C. Rooney
  • 576 Publications • 36,251 Citations
  • S. Rosenberg
  • 1,487 Publications • 203,518 Citations
  • C. Bollard
  • 595 Publications • 14,772 Citations
  • Publications
  • Influence
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.
TLDR
The results demonstrate the superiority of CARs with dual signal domains and confirm a method of comparing CAR-modified T cells within individual patients, thereby avoiding patient-to-patient variability and accelerating the development of optimal T cell immunotherapies.
Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.
TLDR
Polyclonal donor-derived T-cell lines specific for EBV proteins can be used safely to prevent EBV-related immunoblastic lymphoma after allogeneic marrow transplantation and may also be effective in the treatment of established disease.
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
TLDR
EBV-specific donor-type T-cell lines seem to offer safe and effective therapy for control of EBV-associated lymphoproliferation in patients with EBV reactivation after bone-marrow transplantation.
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
TLDR
It is shown in individuals with neuroblastoma that EBV-specific CTLs expressing a chimeric GD2-specific receptor indeed survive longer than T cells activated by the CD3-specific antibody OKT3 and expressing the same chimeric receptor but lacking virus specificity.
Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes
TLDR
These findings support wider use of antigen–specific CTLs in adoptive immunotherapy and restore cellular immune responses against EBV, but also established populations of CTL precursors that could respond to in vivo or ex vivo challenge with the virus for as long as 18 months.
Inducible apoptosis as a safety switch for adoptive cell therapy.
TLDR
The inducible T-cell safety switch based on the fusion of human caspase 9 to a modified human FK-binding protein, allowing conditional dimerization may increase the safety of cellular therapies and expand their clinical applications.
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.
TLDR
It is shown that GD2-CAR T cells can induce complete tumor responses in patients with active neuroblastoma; these CAR T cells may have extended, low-level persistence in patients, and such persistence was associated with longer survival.
Adenovirus infection after pediatric bone marrow transplantation
Retrospective analysis of 206 patients undergoing 215 consecutive bone marrow transplants (BMT) at St Jude Children’s Research Hospital between November 1990 and December 1994 identified 6% (seven…
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells.
TLDR
It is hypothesized that the CD28-OX40-CD3zeta tripartite cytoplasmic domain will provide a full complement of activation, proliferation, and survival signals for enhanced anti-tumor activity.
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes.
TLDR
It is demonstrated that EBV-specific cytotoxic T-cell lines can readily be generated from individuals with NPC, notwithstanding the patients' prior exposure to chemotherapy/radiation, and can be associated with significant antitumor activity.
...
1
2
3
4
5
...